G. Thomas Budd, MD

Appointed
1982

Education & Fellowships

Fellowship - Cleveland Clinic
Medical Oncology
Cleveland, OH USA
1982

Residency - Cleveland Clinic
Internal Medicine
Cleveland, OH USA
1980

Medical Education - University of Kansas School of Medicine
Kansas City, KS USA
1977

Professional Highlights

• Grants.gov ID Number 12301534 Department of Defense
  Primary Immunoprevention of Breast Cancer. 10/1/17–9/30/21
  Role: Partnering Principal Investigator 

  N01-CN-55131-MAO - National Cancer Institute
  Phase I and Pharmacokinetic Trials of Perillyl Alcohol in Patients with a Prior History of Breast Carcinoma
  

  6/30/95 - 6/29/03 (includes no- cost extension)
  Role: Principal Investigator
  
  N01-CN-55119-MAO - National Cancer Institute
  Phase I Multiple Dose Safety and Pharmacokinetic Clinical Trial of Sulindac Sulfone
  6/30/95 - 5/15/97
  G. Thomas Budd, Principal Investigator
  
  5U10 CA004919-47 National Cancer Institute
  Southwest Oncology Group
  

  10/01/87-12/31/09
  Role: Principal Investigator 
  
  PO1 - CA48919-01A2, National Cancer Institute
  Biology of Renal Cell Carcinoma
  RM Bukowski, Principal Investigator
  Project 1, Combination Cytokine Therapy
  G. Thomas Budd, Principal Investigator
  
  
  

Certifications

• Internal Medicine
• Internal Medicine - Medical Oncology

Specialty Interests

Solid tumors, breast cancer, sarcomas, biologic response modifiers, experimental therapeutics, cancer chemoprevention, clinical trials, medical oncology, cancer

Awards & Honors

• Lula Zapis Endowed Chair to support Breast Cancer Research

Memberships

• American Society of Clinical Oncology
• American Association for Cancer Research
• Southwest Oncology Group
• American Medical Association
• American College of Physicians

See publications for G. Thomas Budd, MD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 2/3/2022, Dr. Budd has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Budd receives fees of $5,000 or more per year as a paid consultant, speaker or member of an advisory committee for the following companies:

• Partnership for Health Analytic Research, LLC

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.